Saturday 17 October 2026
Export RDHL’s income statement to Excel — free account
Redhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
0.48
0.02
−4.00%
Follow RDHL
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 6 | 2 | 3 | 4 | 4 | 5 | 3 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1,302.52 | 22.11 | 15.34 | 28.66 | 4.57 | 1.40 | 0.18 | 0.07 | 0.01 | 0.00 |
Altman Z-Score |
5.00 | (0.89) | 2.01 | 2.59 | (1.94) | (3.38) | (5.14) | (22.61) | (33.41) | (24.39) |
Altman Z″-Score (non-manufacturers) |
4.54 | (5.24) | (3.40) | (4.84) | (7.46) | (9.30) | (15.57) | (54.98) | (81.32) | (58.40) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | 31.57 | (2.54) | (1.53) | 5.91 | (3.27) | (3.71) | 7.91 | 0.03 | (8.70) |
P/Operating CF |
(13.19) | (6.41) | (15.65) | (13.00) | (23.15) | (8.07) | (4.50) | (0.93) | (0.06) | (0.01) |
P/B ratio |
2.14 | 2.01 | 2.50 | 3.00 | 21.21 | 13.52 | 0.00 | 0.65 | 6.27 | 0.00 |
Price to Tangible BV |
2.37 | 2.28 | 2.80 | 4.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
660.25 | 10.86 | 8.97 | 21.65 | 5.40 | 1.95 | 2.86 | 6.14 | 6.35 | 6.50 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.41) | (1.00) | (2.18) | (3.34) | (7.15) | (2.57) | (6.05) | (5.63) | (6.21) | (10.11) |
EV/FCF |
(2.27) | (0.97) | (2.11) | (3.24) | (3.39) | (1.41) | (2.13) | (2.16) | (2.29) | (2.72) |
Quick Ratio |
12.37 | 4.03 | 5.22 | 4.62 | 0.80 | 0.86 | 0.36 | 0.45 | 0.32 | 0.21 |
Current Ratio |
12.66 | 4.37 | 5.47 | 5.01 | 0.96 | 1.09 | 0.44 | 0.81 | 0.54 | 0.34 |
Net Debt/EBITDA |
2.17 | 0.89 | 1.36 | 1.04 | (0.86) | (0.75) | (2.28) | (0.43) | 0.79 | 0.53 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 5.15% | 46.10% | 47.04% | 72.52% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.06 | 5.99 | 9.60 | (2.38) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.06 | 0.14 | 0.09 | 0.51 | 0.47 | 0.36 | 0.07 | 0.39 | 0.01 |
Operating CF/Net income |
0.96 | 0.98 | 0.89 | 0.96 | 0.64 | 0.67 | 0.41 | (1.50) | 1.13 | 22.50 |
Capex/Depreciation |
(2.73) | (14.58) | (0.64) | (0.20) | (31.45) | (0.01) | (0.02) | (0.01) | (0.01) | (0.01) |
Interest Coverage |
(81.45) | (674.96) | (235.51) | (98.63) | (4.99) | (4.87) | (1.01) | 1.32 | (4.28) | (5.45) |
| (47.84%) | (84.52%) | (80.66%) | (76.09%) | (206.25%) | (859.70%) | 362.65% | (103.24%) | 632.59% | 206.75% | |
| (41.65%) | (69.24%) | (64.83%) | (61.98%) | (59.90%) | (54.09%) | (42.15%) | 26.29% | (40.24%) | (1.98%) | |
ROIC |
0.00% | 0.00% | 0.00% | (169.34%) | (59.26%) | (90.38%) | (86.85%) | 0.00% | 0.00% | (1,671.30%) |
Return on Tangible Assets |
(46.90%) | (113.64%) | (83.36%) | (98.78%) | 3,417.36% | (1,184.20%) | 64.54% | (655.23%) | 81.24% | 3.39% |
Average Days of Receivables |
357.77 | 139.19 | 41.83 | 70.55 | 162.51 | 134.82 | 203.89 | 144.83 | 115.22 | 100.82 |
Research and Development Expense of Revenue |
24,991.09% | 822.79% | 297.39% | 276.89% | 25.62% | 34.40% | 11.78% | 54.03% | 19.74% | 707.34% |
Selling, General and Administrative Expense of Revenue |
5,349.50% | 500.10% | 239.14% | 473.92% | 116.01% | 102.60% | 103.61% | 474.35% | 60.76% | 2,158.04% |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.09 | 0.23 | 0.49 | 0.40 | 0.41 | 0.24 | 0.31 | 0.21 |
Share Based Compensation of Revenue |
1,662.38% | 55.78% | 32.03% | 48.12% | 6.53% | 11.91% | 9.18% | 25.22% | 8.27% | 159.79% |
Graham Net Nets |
0.42 | 0.43 | 0.36 | 0.22 | (0.33) | (0.69) | (11.13) | (2.01) | (16.36) | (161.27) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,472.10 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(21.44%) | (48.73%) | (31.71%) | (21.91%) | (26.49%) | (81.78%) | (639.15%) | (1,673.06%) | (9,833.60%) | (59,288.03%) |
Free Cash Flow Yield |
(22.30%) | (50.68%) | (27.76%) | (23.31%) | (34.80%) | (98.80%) | (758.96%) | (3,865.09%) | (22,118.96%) | (115,100.55%) |
Revenue per Share |
7.83 | 226.38 | 361.90 | 211.82 | 1,768.10 | 1,844.24 | 1,003.25 | 25.20 | 6.53 | 0.09 |
Operating CF per Share |
(2,190.54) | (2,529.32) | (1,491.86) | (1,372.02) | (1,334.59) | (1,398.86) | (473.78) | (138.25) | (7.60) | (3.06) |
Capex per Share |
(9.30) | (66.72) | (2.51) | (6.83) | (1,477.31) | (2.47) | (3.21) | (0.04) | (0.01) | 0.00 |
Free Cash Flow per Share |
(2,199.84) | (2,596.05) | (1,494.37) | (1,378.86) | (2,811.90) | (1,401.33) | (477.00) | (138.29) | (7.61) | (3.06) |
Cash per Share |
5,128.22 | 2,610.45 | 2,302.38 | 1,611.85 | 818.49 | 817.29 | 584.14 | 24.54 | 3.75 | 1.26 |
Shareholders Equity per Share |
4,860.54 | 2,546.05 | 2,215.84 | 2,020.27 | 380.88 | 190.86 | (785.71) | 7.99 | (3.80) | 1.35 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4,860.54 | 2,546.05 | 2,215.84 | 2,020.27 | 380.88 | 190.86 | (785.71) | 7.99 | (3.80) | 1.35 |
Free Cash Flow |
(28.38) | (45.95) | (34.52) | (40.95) | (102.35) | (65.16) | (29.38) | (35.83) | (9.38) | (9.66) |
Working Capital |
62.46 | 39.85 | 46.41 | 42.60 | (2.74) | 7.68 | (111.55) | (3.84) | (10.31) | (12.69) |
Capital Expenditures |
(0.12) | (1.18) | (0.06) | (0.20) | (53.77) | (0.11) | (0.20) | (0.01) | (0.01) | 0.00 |
Net Current Asset Value |
56.30 | 39.40 | 45.56 | 39.12 | (95.88) | (83.16) | (121.37) | (4.84) | (10.81) | (14.55) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.19 | 0.29 | 0.01 | 0.03 | 0.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.27 | 0.35 | 0.55 | 4.37 | 3.35 | 31.73 | 16.24 | 10.31 | 4.59 | 8.35 |
Cash ROIC |
(22.02%) | (50.35%) | (33.07%) | (36.67%) | (80.75%) | (49.32%) | (28.58%) | (425.14%) | 14,209.09% | (117.20%) |
Accounts Receivable Turnover |
0.09 | 4.93 | 6.73 | 5.79 | 4.31 | 2.84 | 1.87 | 0.35 | 3.14 | 0.22 |
Accounts Payable Turnover |
0.00 | 0.87 | 0.70 | 0.60 | 4.69 | 4.26 | 4.19 | 0.92 | 1.44 | — |
Inventory Turnover |
— | 0.82 | 3.99 | 1.70 | 8.78 | 4.63 | 2.58 | 0.45 | 0.79 | — |
Average Days of Payables |
0.00 | 824.94 | 427.66 | 676.03 | 114.30 | 86.17 | 46.31 | 345.90 | 133.56 | — |
Days of Inventory on Hand |
— | 112.11 | 98.94 | 304.09 | 64.57 | 109.41 | 120.54 | 463.14 | 417.49 | — |
Average Receivables |
1.18 | 0.81 | 1.24 | 1.09 | 14.94 | 30.17 | 33.10 | 18.56 | 2.57 | 1.31 |
Average Payables |
1.79 | 2.43 | 4.06 | 3.75 | 7.87 | 11.61 | 7.95 | 3.75 | 2.22 | — |
Average Inventory |
— | 2.58 | 0.71 | 1.33 | 4.20 | 10.67 | 12.91 | 7.70 | 4.02 | — |
Average Assets |
70.52 | 65.78 | 59.88 | 68.26 | 127.17 | 180.71 | 170.03 | 90.96 | 20.55 | 21.69 |
Average Common Equity |
61.39 | 53.88 | 48.13 | 55.59 | 36.93 | 11.37 | (19.76) | (23.17) | (1.31) | (0.21) |
Columns are period end dates · fundamentals updated 2 Oct 2026